BR112014006405A2 - anticorpo, conjunto, e, método para medir um complexo de afinidade - Google Patents

anticorpo, conjunto, e, método para medir um complexo de afinidade

Info

Publication number
BR112014006405A2
BR112014006405A2 BR112014006405A BR112014006405A BR112014006405A2 BR 112014006405 A2 BR112014006405 A2 BR 112014006405A2 BR 112014006405 A BR112014006405 A BR 112014006405A BR 112014006405 A BR112014006405 A BR 112014006405A BR 112014006405 A2 BR112014006405 A2 BR 112014006405A2
Authority
BR
Brazil
Prior art keywords
antibody
measuring
affinity complex
present
affinity
Prior art date
Application number
BR112014006405A
Other languages
English (en)
Inventor
Oka Asako
Goishi Katsutoshi
Omi Kazuya
Shirakawa Takashi
Sakyu Takuya
Ando Tsuyoshi
Uchida Yoshiaki
Original Assignee
Fujirebio Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Kk filed Critical Fujirebio Kk
Publication of BR112014006405A2 publication Critical patent/BR112014006405A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1 / 1 resumo “anticorpo, conjunto, e, mã‰todo para medir um complexo de afinidade” a presente invenã§ã£o diz respeito a um meio e um mã©todo para medir especificamente uma substã¢ncia tal como uma substã¢ncia pequena com maior sensibilidade para um mã©todo sanduã­che. especificamente, a presente invenã§ã£o diz respeito a um anticorpo capaz de ligar especificamente em um complexo de afinidade e um mã©todo de mediã§ã£o do complexo de afinidade compreendendo medir o complexo de afinidade usando o anticorpo capaz de ligar especificamente no complexo de afinidade. o anticorpo da presente invenã§ã£o pode ser um anticorpo de comprimento total. o anticorpo da presente invenã§ã£o pode tambã©m ter uma regiã£o derivada de uma imunoglobulina de um animal com uma capacidade de conversã£o genã©tica (por exemplo, uma regiã£o determinante de complementaridade, uma regiã£o da estrutura, ou uma regiã£o variã¡vel). exemplos de pelo menos um fator que constitui o complexo de afinidade incluem uma substã¢ncia pequena ou uma proteã­na (por exemplo, anticorpo).
BR112014006405A 2011-09-21 2012-07-04 anticorpo, conjunto, e, método para medir um complexo de afinidade BR112014006405A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011206162 2011-09-21
JP2012006359 2012-01-16
PCT/JP2012/067062 WO2013042426A1 (ja) 2011-09-21 2012-07-04 親和性複合体に対する抗体

Publications (1)

Publication Number Publication Date
BR112014006405A2 true BR112014006405A2 (pt) 2017-04-04

Family

ID=47914207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006405A BR112014006405A2 (pt) 2011-09-21 2012-07-04 anticorpo, conjunto, e, método para medir um complexo de afinidade

Country Status (13)

Country Link
US (1) US9599608B2 (pt)
EP (1) EP2759551B1 (pt)
JP (1) JP6156144B2 (pt)
KR (1) KR101720394B1 (pt)
CN (1) CN103827145A (pt)
AU (1) AU2012310880B2 (pt)
BR (1) BR112014006405A2 (pt)
CA (1) CA2849274C (pt)
IL (1) IL231404A0 (pt)
IN (1) IN2014CN02113A (pt)
RU (1) RU2014115676A (pt)
TW (1) TW201313743A (pt)
WO (1) WO2013042426A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2759550T3 (pl) 2013-01-28 2019-01-31 Diasorin S.P.A. Sposób i zestaw do wykrywania 1,25-dihydroksywitaminy D i powiązane przeciwciała
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
US10983136B2 (en) 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
AU2014215330B2 (en) 2013-02-06 2017-02-02 Fujirebio Inc. Vitamin D measurement method and measurement kit
JP6512214B2 (ja) * 2014-02-25 2019-05-15 富士レビオ株式会社 改変単量体ＩｇＭ
WO2017109290A1 (en) 2015-12-21 2017-06-29 Turun Yliopisto Antibodies against immunocomplexes comprising cyanobacterial cyclic peptide hepatotoxins
AU2017209523A1 (en) * 2016-01-22 2018-08-09 Affimedix, Inc. Device for detection of vitamin D metabolites
CN106244562B (zh) * 2016-05-20 2019-07-23 杭州奥泰生物技术股份有限公司 杂交瘤细胞株及其分泌的抗25羟基维生素d3单克隆抗体和应用
CN109863406B (zh) * 2016-07-29 2023-04-14 Diazyme研究室有限公司 用于测定维生素d的方法和成分
AU2018270515A1 (en) * 2017-05-19 2019-12-05 The Regents Of The University Of California Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies
CN111512154B (zh) 2017-12-25 2022-05-27 富士瑞必欧株式会社 针对大环内酯类免疫抑制剂的血液检测方法
EP4063514A4 (en) * 2019-11-20 2023-11-01 Tosoh Corporation MEASUREMENT METHOD USING AN ANTI-IMMUNOCOMPLEX ANTIBODY
JP7434824B2 (ja) * 2019-11-20 2024-02-21 東ソー株式会社 抗イムノコンプレックス抗体を用いた測定方法
CN113125696B (zh) * 2019-12-31 2024-03-26 科美博阳诊断技术(上海)有限公司 一种雌二醇均相化学发光检测试剂盒及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3364347D1 (en) * 1982-04-09 1986-08-07 Fujirebio Kk Anti immune complex antibody and preparation thereof
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8408193D0 (en) 1984-03-30 1984-05-10 Cambridge Patent Dev Antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223441A (en) 1986-10-09 1993-06-29 Syntex (U.S.A.) Inc. Receptors for immune complexes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5187065A (en) * 1989-12-22 1993-02-16 Schutzer Steven E Method and materials for detecting lyme disease
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP1707051B1 (en) 1997-02-28 2010-01-13 Kyowa Hakko Kirin Co., Ltd. Human chromosome fragment, and vector containing it
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
US7122339B2 (en) 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
AU777420B2 (en) 1999-06-04 2004-10-14 Tranxenogen, Inc. Methods for manipulating the avian genome
JP4228095B2 (ja) * 1999-12-17 2009-02-25 東ソー株式会社 免疫測定方法および免疫測定試薬
JP2001231403A (ja) 2000-02-18 2001-08-28 Kirin Brewery Co Ltd 改変された外来染色体あるいはその断片を保持する非ヒト動物
EP1343880B1 (en) 2000-11-17 2009-05-27 Kyowa Hakko Kirin Co., Ltd. Expression of xenogenous (human) immunoglobulins in cloned, transgenic bovine
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1536004B1 (en) * 2002-07-30 2010-12-01 Riken Method of promoting homologous recombination of somatic cells and method of constructing specific antibody
FI20022048A0 (fi) * 2002-11-18 2002-11-18 Valtion Teknillinen Ei-kompetetiivinen immunomääritys pienille analyyteille
JP5319863B2 (ja) 2002-12-26 2013-10-16 独立行政法人理化学研究所 体細胞相同組換えの誘発方法
JP2007533328A (ja) 2004-04-22 2007-11-22 キリンホールディングス株式会社 トランスジェニック動物及びその用途
CN101084317A (zh) 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
JP4892717B2 (ja) * 2005-03-31 2012-03-07 国立大学法人広島大学 ニワトリキメラ抗体およびその利用
DE602006006200D1 (de) * 2005-09-29 2009-05-20 Roche Diagnostics Gmbh Antikörper gegen 25-hydroxyvitamin d
FI20075251A0 (fi) 2007-04-13 2007-04-13 Hytest Oy Immunomääritys epästabiilien antigeenien määrittämiseksi
JP2009082033A (ja) 2007-09-28 2009-04-23 Kaneka Corp 完全ヒト型抗体生産法
FI20085579A0 (fi) * 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
US20110097733A1 (en) * 2009-10-27 2011-04-28 Michel Anciaux Process for the production of a hybridoma and antibody obtained therefrom, able to recognize more than one vitamin d metabolite

Also Published As

Publication number Publication date
JPWO2013042426A1 (ja) 2015-03-26
US20150037813A1 (en) 2015-02-05
WO2013042426A1 (ja) 2013-03-28
AU2012310880A1 (en) 2014-04-10
IL231404A0 (en) 2014-04-30
JP6156144B2 (ja) 2017-07-05
EP2759551A4 (en) 2015-03-04
KR20140044940A (ko) 2014-04-15
RU2014115676A (ru) 2015-10-27
CA2849274C (en) 2018-12-04
TW201313743A (zh) 2013-04-01
CA2849274A1 (en) 2013-03-28
US9599608B2 (en) 2017-03-21
KR101720394B1 (ko) 2017-03-27
EP2759551A1 (en) 2014-07-30
CN103827145A (zh) 2014-05-28
IN2014CN02113A (pt) 2015-05-29
AU2012310880B2 (en) 2015-12-03
EP2759551B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
BR112014006405A2 (pt) anticorpo, conjunto, e, método para medir um complexo de afinidade
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
CR20120371A (es) Antagonistas de pcsk9
CL2013003640A1 (es) Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11).
BR112015022141A2 (pt) Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrna
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
GB201108236D0 (en) Method
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
WO2012075506A3 (en) Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
WO2012016227A3 (en) Antibodies with modified isoelectric points
EA201692242A1 (ru) Композиции с высокой концентрацией антител
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
WO2012174049A3 (en) Compositions and methods for controlling neuronal excitation
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
WO2010133963A3 (en) Forming sample combinations using liquid bridge systems
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
BR112012019475A8 (pt) uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
GB201313794D0 (en) Assay assembly and method
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
WO2017122089A8 (en) METHOD FOR MEASURING TEAR CONSISTENTS IN A TEAR SAMPLE
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
WO2013165969A3 (en) Methods and kits for diagnosing heparin-induced thrombocytopenia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]